SCHEMBL853813

SCHEMBL853813

CC=CCCC(C)=C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14921365 0.79 TOP1 (0.36)
SCHEMBL13280250 0.79 TOP1 (0.36)
SCHEMBL10342113 0.78 ALDH1A1 (0.46)
SCHEMBL12989000 0.78
SCHEMBL12988996 0.78
SCHEMBL10342115 0.78 ALDH1A1 (0.46)
SCHEMBL12988999 0.78
SCHEMBL5390957 0.75
SCHEMBL5390953 0.75
SCHEMBL3406148 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 351 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024133845-A1 CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG TUBULIS GMBH (DE) 2024-06-27 WO disclosed
CN-111569086-B Methylene carbamate linkers for use with target-drug conjugates 西雅图基因公司 2024-06-21 CN disclosed
CN-111558049-B Methylene carbamate linkers for use with target-drug conjugates 西雅图基因公司 2024-06-21 CN disclosed
US-20240190958-A1 NOVEL ANTIBODY DRUG CONJUGATES WITH NOVEL NAPI2B ANTIBODIES, THERAPEUTIC METHODS AND USES THEREOF TUBULIS GMBH (DE) 2024-06-13 US disclosed
EP-4380978-A1 METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA Genentech, Inc. (US) 2024-06-12 EP disclosed
EP-4378482-A2 DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES Seagen Inc. (US) 2024-06-05 EP disclosed
EP-3280402-B1 TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING BIOMENDICS LLC (US) 2024-06-05 EP disclosed
EP-4367094-A1 ULTRAVIOLET AND VISIBLE RADIATION ABSORBING COMPOUNDS Elkimia Inc. (CA) 2024-05-15 EP disclosed
US-20240139275-A1 WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES SEAGEN INC (US) 2024-05-02 US disclosed
US-20240131176-A1 SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY SEAGEN INC (US) 2024-04-25 US disclosed
EP-1542980-A1 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR Inotek Pharmaceuticals Corporation (US) 2005-06-22 EP disclosed
US-20050101565-A1 Pharmaceutical compositions and methods for treating, preventing, and managing cholesterol, dyslipidemia, and related disorders ESPERION THERAPEUTICS, INC. 2005-05-12 US disclosed
EP-1519751-A2 COMPOSITIONS COMPRISING PANTHETINE FOR THE TREATMENT OF DYSLIPIDEMIA Esperion Therapeutics Inc. (US) 2005-04-06 EP disclosed
EP-1487436-A1 COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS Signal Pharmaceuticals, Inc. (US) 2004-12-22 EP disclosed
EP-1476141-A2 TAMPER-RESISTANT TRANSDERMAL OPIOID DELIVERY DEVICES Euro-Celtique, S.A. (LU) 2004-11-17 EP disclosed
WO-2004009563-A1 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR INOTEK PHARMACEUTICALS CORPORATION (US) 2004-01-29 WO disclosed
US-20040019208-A1 5-Aryltetrazole Compounds, compositions thereof, and uses therefor INOTEK PHARMACEUTICALS CORPORATION 2004-01-29 US disclosed
WO-2004004774-A2 COMPOSITIONS COMPRISING PANTHETINE FOR THE TREATMENT OF DYSLIPIDEMIA ESPERION THERAPEUTICS, INC. (US) 2004-01-15 WO disclosed
WO-2003075917-A1 COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS SIGNAL PHARMACEUTICALS, INC. (US) 2003-09-18 WO disclosed
WO-2003070191-A2 TAMPER-RESISTANT TRANSDERMAL OPIOID DELIVERY DEVICES EURO-CELTIQUE, S.A. (LU) 2003-08-28 WO disclosed